Oncology-focused biotech company Exelixis Inc (NASDAQ:EXEL) and US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, on Monday announced a clinical development collaboration to evaluate zanzalintinib, Exelixis' investigational tyrosine kinase inhibitor, in combination with KEYTRUDA (pembrolizumab) for head and neck cancer and with WELIREG (belzutifan) for renal cell carcinoma.
Under the terms of the collaboration, Merck will supply KEYTRUDA for the ongoing, Exelixis-sponsored STELLAR-305 trial in head and neck squamous cell carcinoma and will sponsor a phase 1/2 trial and two phase 3 pivotal trials in renal cell carcinoma.
Merck will fund one of these phase 3 studies, and Exelixis will co-fund the phase 1/2 trial and the other phase 3 study, as well as supply zanzalintinib and cabozantinib. Exelixis maintains all global commercial and marketing rights to zanzalintinib.
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial
Turnstone Biologics announces strategic restructuring
Pfizer's TALZENNA plus XTANDI shows promise in prostate cancer treatment
GenesisCare UK selects RayStation for radiotherapy system upgrade
Boehringer Ingelheim and Circle Pharma collaborate on cancer treatment
Petauri launches medical communications platform Petauri Advance
Bayer and MOMA Therapeutics enter oncology collaboration
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics
MediLink enters clinical trial collaboration and supply agreement with Amgen